Anti-CD19 chimeric antigen receptor T cell therapy - The Beijing Pregene Science and Technology Company

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - The Beijing Pregene Science and Technology Company

Alternative Names: CART-19 cells - Beijing Pregene Science and Technology Company; CD19 specific chimeric antigen receptor T-cells - Beijing Pregene Science and Technology Company

Latest Information Update: 15 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Beijing Pregene Science and Technology
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma
  • Phase I Acute lymphoblastic leukaemia

Most Recent Events

  • 01 May 2017 Phase-I/II clinical trials in B-cell lymphoma (In the elderly, Second-line therapy or greater, In adults, Adjunctive treatment, Refractory metastatic disease) in China (IV) (NCT03146533)
  • 01 Sep 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater, In adolescents, In adults, In children, In the elderly) in China (Parenteral) (NCT02924753)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top